NephCure, a nonprofit organization committed to finding better treatments and a cure for rare kidney diseases, has announced that the first IgA Nephropathy (IgAN) Awareness Day will occur on September 26, 2024. The day is intended to promote the importance of early diagnosis and proactive treatment of IgAN and provide critical resources for affected patients. ...
Nephrology Times
Nephrology Times delivers the latest news in kidney-related treatments and technologies with the goal of better informing care decisions and improving patient outcomes.
Advertisement
Sponsored Content
Qasim Butt, MD, describes the importance of hyperkalemia management and how LOKELMA can help.
Advertisement
Latest News
NephCure has announced the first IgA Nephropathy (IgAN) Awareness Day, happening September 26, 2024.
What is the relationship between blood urea nitrogen-to-serum albumin ratio and mortality in ICU patients with T2D and CKD?
The FDA has granted full approval to sparsentan to slow kidney function decline in adults with primary IgA nephropathy.
eGenesis has received financing to help advance an engineered kidney, EGEN-2784, to a first-in-human study for transplant.
How does early vs delayed treatment with long-acting ESAs affect renal and cardiovascular outcomes in patients with NDD-CKD?
Makana Therapeutics has discovered a fourth pig gene that, when inactivated, could greatly reduce organ rejection risk.
ProKidney halted one of two phase 3 trials of rilparencel, or REACT, a cell therapy for kidney disease.
ANNA's national president spoke about its support for nephrology nurses and the upcoming 2024 Nephrology Nursing Summit.
Researchers used KPIs to evaluate anemia and iron status management in children on hemodialysis.
A study explored the relationship between intake of dietary fiber and hyperkalemia in patients on maintenance hemodialysis.
Expert Interviews
In Print
American Transplant Congress, 61st ERA Congress, AKI risk prediction, effects of a lifestyle intervention, and more.
NKF Spring Clinical Meetings, ETC payment model, ozone and ESRD risk, IgAN treatments, and more.
Conferences
ATC provides a forum for exchange of new scientific and clinical information relevant to transplantation.
The annual nephrology meeting organized by the European Renal Association
The National Kidney Foundation's premier educational event designed for the interprofessional kidney health team
The annual scientific, educational, and networking meeting of the International Society of Nephrology
Podcasts
It's time for another NephJC draft! This time the 2024 KDIGO CKD guideline draft is on the clock!
Results of Nefecon (budesonide) for IgA nephropathy set the stage for a glomerulonephritis renaissance.
Vlado Perkovic presented results from the FLOW trial at the 61st ERA Congress, making headlines worldwide.
A blood test may help nephrologists answer the question, “Is this preeclampsia, proteinuric CKD, or a lupus flare?”
Expert Columns
The four-pillar approach to treating diabetic kidney disease (DKD) has been endorsed by high-quality trials, such as FLOW.
It is essential for nephrology practices and dialysis centers to have backup methods for processing claims.
IgA nephropathy (IgAN) is on the cusp of a transformational change in its treatment.
Medicare Advantage plans are posing significant operational and financial hurdles for dialysis programs.
APRIL has emerged as a critical factor in the pathogenesis of IgAN and is the focus of several clinical development programs.
The benefit-risk ratio and considerations about unmet need are worth considering.
Knowledge Hubs
Advertisement
Advertisement
Nephrology Times Chair
Ajay K. Singh, MBBS, FRCP, MBASenior Nephrologist, Brigham and Women’s Hospital | Senior Associate Dean, Harvard Medical School
Editorial Board
Mohamed G. Atta, MD, MPHProfessor of Medicine, Johns Hopkins School of Medicine
Timothy E. Bunchman, MDProfessor and Director, Pediatric Nephrology, Transplantation, and Rheumatology, Children’s Hospital of Richmond at VCU
Suphamai Bunnapradist, MD, MSProfessor of Medicine, David Geffen School of Medicine at UCLA | Research Director, Kidney Transplant Program, UCLA
Fernando C. Fervenza, MD, PhDProfessor of Medicine, Division of Nephrology and Hypertension, Mayo Clinic
Kenneth A. Liss, DOPartner, Hypertension and Nephrology Association, Eatontown, NJ
Joel M. Topf, MD, FACPAssistant Clinical Professor of Medicine, Oakland University William Beaumont School of Medicine
